Literature DB >> 9328129

Phenotype, cytokine production and cytolytic capacity of fresh (uncultured) tumour-infiltrating T lymphocytes in human renal cell carcinoma.

L E Van den Hove1, S W Van Gool, H Van Poppel, L Baert, L Coorevits, B Van Damme, J L Ceuppens.   

Abstract

We investigated the phenotype and functional capacities of tumour-infiltrating lymphocytes (TIL), freshly isolated from primary renal cell carcinoma (RCC) specimens (n = 20). Three-colour flow cytometry immunophenotyping revealed that RCC TIL consist mainly of CD3+ T cells, with a clear predominance of CD4- CD8+ over CD4+ CD8- T cells, and a marked population of CD4+ CD8+ T cells. Natural killer (NK) cells were also strongly represented (> 25% in 15 of 20 tumour samples), while B cells constituted a minor TIL subset (< 5% in 18 of 20 tumour samples). More importantly, the T and NK cells within the tumour displayed a significantly higher expression of the early activation marker CD69 than their counterparts in adjacent normal renal tissue and in peripheral blood. Expression of CD54 and of HLA-DR was also elevated on CD3+ TIL, and HLA-DR expression was further vigorously up-regulated following ex vivo stimulation with anti-CD3, all suggesting enhanced immune activity within the tumour microenvironment. CD3+ CD4+ TIL displayed a normal capacity to up-regulate CD25 expression and to secrete both Th1-type (IL-2, tumour necrosis factor-alpha (TNF-alpha) and interferon-gamma (IFN-gamma)) and Th2-type (IL-4, IL-5 and IL-10) cytokines upon triggering with anti-CD3. Furthermore, cytokine production was susceptible to modulation by CD28 costimulation. CD3+ CD8+ TIL, on the other hand, consistently demonstrated a poor up-regulation of CD25 upon triggering with anti-CD3, and displayed poor ex vivo cytolytic activity in an anti-CD3-redirected 4-h cytotoxicity assay against murine P815 cells. Collectively, our findings indicate that the CD3+ CD4+ TIL in RCC have normal functional capacities, whereas the proportionally major CD3+ CD8+ TIL are functionally impaired. The relevance of these findings to the in vivo local immune response in RCC is discussed.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9328129      PMCID: PMC1904758          DOI: 10.1046/j.1365-2249.1997.4771375.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  23 in total

Review 1.  Th1/Th2 balance in cancer, transplantation and pregnancy.

Authors:  M R Shurin; L Lu; P Kalinski; A M Stewart-Akers; M T Lotze
Journal:  Springer Semin Immunopathol       Date:  1999

Review 2.  Assessing Tumor-Infiltrating Lymphocytes in Solid Tumors: A Practical Review for Pathologists and Proposal for a Standardized Method from the International Immuno-Oncology Biomarkers Working Group: Part 2: TILs in Melanoma, Gastrointestinal Tract Carcinomas, Non-Small Cell Lung Carcinoma and Mesothelioma, Endometrial and Ovarian Carcinomas, Squamous Cell Carcinoma of the Head and Neck, Genitourinary Carcinomas, and Primary Brain Tumors.

Authors:  Shona Hendry; Roberto Salgado; Thomas Gevaert; Prudence A Russell; Tom John; Bibhusal Thapa; Michael Christie; Koen van de Vijver; M V Estrada; Paula I Gonzalez-Ericsson; Melinda Sanders; Benjamin Solomon; Cinzia Solinas; Gert G G M Van den Eynden; Yves Allory; Matthias Preusser; Johannes Hainfellner; Giancarlo Pruneri; Andrea Vingiani; Sandra Demaria; Fraser Symmans; Paolo Nuciforo; Laura Comerma; E A Thompson; Sunil Lakhani; Seong-Rim Kim; Stuart Schnitt; Cecile Colpaert; Christos Sotiriou; Stefan J Scherer; Michail Ignatiadis; Sunil Badve; Robert H Pierce; Giuseppe Viale; Nicolas Sirtaine; Frederique Penault-Llorca; Tomohagu Sugie; Susan Fineberg; Soonmyung Paik; Ashok Srinivasan; Andrea Richardson; Yihong Wang; Ewa Chmielik; Jane Brock; Douglas B Johnson; Justin Balko; Stephan Wienert; Veerle Bossuyt; Stefan Michiels; Nils Ternes; Nicole Burchardi; Stephen J Luen; Peter Savas; Frederick Klauschen; Peter H Watson; Brad H Nelson; Carmen Criscitiello; Sandra O'Toole; Denis Larsimont; Roland de Wind; Giuseppe Curigliano; Fabrice André; Magali Lacroix-Triki; Mark van de Vijver; Federico Rojo; Giuseppe Floris; Shahinaz Bedri; Joseph Sparano; David Rimm; Torsten Nielsen; Zuzana Kos; Stephen Hewitt; Baljit Singh; Gelareh Farshid; Sibylle Loibl; Kimberly H Allison; Nadine Tung; Sylvia Adams; Karen Willard-Gallo; Hugo M Horlings; Leena Gandhi; Andre Moreira; Fred Hirsch; Maria V Dieci; Maria Urbanowicz; Iva Brcic; Konstanty Korski; Fabien Gaire; Hartmut Koeppen; Amy Lo; Jennifer Giltnane; Marlon C Rebelatto; Keith E Steele; Jiping Zha; Kenneth Emancipator; Jonathan W Juco; Carsten Denkert; Jorge Reis-Filho; Sherene Loi; Stephen B Fox
Journal:  Adv Anat Pathol       Date:  2017-11       Impact factor: 3.875

3.  The high-resolution structure of the extracellular domain of human CD69 using a novel polymer.

Authors:  Petr Kolenko; Tereza Skálová; Ondrej Vanek; Andrea Stepánková; Jarmila Dusková; Jindrich Hasek; Karel Bezouska; Jan Dohnálek
Journal:  Acta Crystallogr Sect F Struct Biol Cryst Commun       Date:  2009-11-27

Review 4.  Tissue-Resident Lymphocytes in the Kidney.

Authors:  Jan-Eric Turner; Martina Becker; Hans-Willi Mittrücker; Ulf Panzer
Journal:  J Am Soc Nephrol       Date:  2017-11-01       Impact factor: 10.121

5.  Immune signature of tumor infiltrating immune cells in renal cancer.

Authors:  Katharina Geissler; Paolo Fornara; Christine Lautenschläger; Hans-Jürgen Holzhausen; Barbara Seliger; Dagmar Riemann
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

6.  JAK3/STAT5/6 pathway alterations are associated with immune deviation in CD8 T cells in renal cell carcinoma patients.

Authors:  Elisabetta Cavalcanti; Margherita Gigante; Vito Mancini; Michele Battaglia; Pasquale Ditonno; Carmela Capobianco; Raffaele I Cincione; Francesco P Selvaggi; Wolfgang Herr; Walter J Storkus; Loreto Gesualdo; Elena Ranieri
Journal:  J Biomed Biotechnol       Date:  2010-03-22

7.  Distinctive features of the differentiated phenotype and infiltration of tumor-reactive lymphocytes in clear cell renal cell carcinoma.

Authors:  Qiong J Wang; Ken-Ichi Hanada; Paul F Robbins; Yong F Li; James C Yang
Journal:  Cancer Res       Date:  2012-10-15       Impact factor: 12.701

8.  Dysfunctional DC subsets in RCC patients: ex vivo correction to yield an effective anti-cancer vaccine.

Authors:  M Gigante; A Blasi; A Loverre; V Mancini; M Battaglia; F P Selvaggi; E Maiorano; A Napoli; G Castellano; W J Storkus; L Gesualdo; E Ranieri
Journal:  Mol Immunol       Date:  2008-11-28       Impact factor: 4.407

Review 9.  Modification of the tumor microenvironment as a novel target of renal cell carcinoma therapeutics.

Authors:  James H Finke; Pat A Rayman; Jennifer S Ko; Judy M Bradley; Sandra J Gendler; Peter A Cohen
Journal:  Cancer J       Date:  2013 Jul-Aug       Impact factor: 3.360

10.  TCRalphabeta+/CD4+ large granular lymphocytosis: a new clonal T-cell lymphoproliferative disorder.

Authors:  Margarida Lima; Julia Almeida; Maria Dos Anjos Teixeira; Maria del Carmen Alguero Md; Ana Helena Santos; Ana Balanzategui; Maria Luís Queirós; Paloma Bárcena; Antonio Izarra; Sónia Fonseca; Clara Bueno; Benvindo Justiça; Marcos Gonzalez; Jesús F San Miguel; Alberto Orfao
Journal:  Am J Pathol       Date:  2003-08       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.